Alberto R. R.
- Country
- Spain
- Department
- Servicio de Reumatología
Research Overview
- A Randomized, Double‑Blind, Placebo‑Controlled Trial of Oral Nerandomilast (BI 1015550) in Patients with Systemic Sclerosis
- Efficacy and Safety Evaluation of Nerandomilast in Systemic Autoimmune Rheumatic Diseases-Associated Interstitial Lung Diseases: A Randomized, Double-Blind, Placebo-Controlled Trial
Data & Insights
Has run more than one trial at 14 of 120 partner sites.
Specializations
Oncologic Therapeutics
The investigator directs studies in solid tumor oncology.
- HER2‑negative breast cancer
- PIK3CA‑mutated breast cancer
- non‑small cell lung cancer
- urothelial carcinoma
- melanoma
Research emphasizes targeted therapy and immunotherapy in advanced malignancies.
Cardiovascular Medicine
Clinical activity includes trials on cardiovascular disease.
- acute coronary syndrome
- heart failure
- atrial fibrillation with antithrombotic strategies
- coronary artery disease
- spontaneous coronary artery dissection
Focus is on innovative antiplatelet and cardioprotective agents for ischemic heart conditions.
Autoimmune and Inflammatory Disorders
The investigator evaluates therapies for systemic autoimmune diseases.
- rheumatoid arthritis
- systemic lupus erythematosus
- Sjögren's disease
- Crohn's disease
- ulcerative colitis
Efforts target disease modification in immune‑mediated gastrointestinal disorders.
Metabolic and Rare Diseases
Research extends to metabolic and rare protein‑misfolding disorders.
- type 2 diabetes mellitus
- severe hypertriglyceridemia
- hereditary transthyretin amyloidosis
- Alzheimer’s disease
- amyloid cardiomyopathy
Investigations aim at disease‑modifying agents for protein aggregation pathologies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.